Documente online.
Username / Parola inexistente
  Zona de administrare documente. Fisierele tale  
Am uitat parola x Creaza cont nou
  Home Exploreaza
Upload


loading...

















































Markerii tumorali

medicina












ALTE DOCUMENTE

CODUL DEONTOLOGIC AL CJU BĂLŢI
BOLILE ENDOCRINE - Bolile glandei tiroide
Bronsita cronica. Emfizemul pulmonar. Obstructia cailor respiratorii.
VISCUL (Viscum album)
MALFORMAŢIILE CONGENITALE ALE APARATULUI URO-GENITAL
Influenta alcoolului asupra sistemului nervos
Adrenalina, solutie injectabila
SISTEMUL NERVOS VEGETATIV
Inima - motorul organismului
ALTI FAURITORI DE MIRACOLE

Markerii tumorali

Definitie




Antigenul tumoral CA 27-29

Ser

Carcinom hepatocelular, cancer pulmonar,

Alfa-fetoproteina (AFP) (

Ser

Mielom si limfom

B2M (Beta-2 microglobulina)

Ser

Canver ovarian, mamar, pulmonar



Antigenul tumoral CA-15-3

Ser

Cancer pancreatic

Antigenul tumoral CA 15-3

Ser

Cancer ovarian

Antigenul tumoral CA-72-4

Antigenul tumoral CA-125

Ser

Cancer tiroidian

Tiroglobulina, hormonului paratiroidian calcitonina

Ser

Cancer pancreatic, tiroidian, cervix, de vezica, colorectal, pulmonar,

Antigen carcinoembrionic (ACE)

Ser

Neuroblastoma, cancer pulmonar (celule mici)

Enolaza neuro specifica (ENS)

Ser

Prostata

Antigen specific prostatic (ASP)

Antigenul specific prostatic membranar

Ser

Melanom

Tirozinaza.


Melanom-metastaza

S-100,

Ser

Melanom-metastaza

TA-90

Ser

Cancer tiroidian

Tiroglobulina

Ser

Cancer testicular

Gonadotropina chorionica




Ser, urina

Mielom

Imunoglobuline monoclonale

Ser, urina

Leucemie

Alterari citogenice numeroase

Ser, urina

Cancer de vezica

NMP22

Urina

Cancer de vezica

Antigen tumoral vezicular BTA (Bladder tumor antigen)

Urina


Arden KC, Anderson MJ, Finckenstein FG, Czekay S, Cavenee WK. Detection of the t(2:13) chromosomal translocation in alveolar rhabdomyosarcomah using the reverse transcriptase polymerase chain reaction. Genes Chrom Cancer


Ballesta AM, Molina R, Filella X, Jo J, Gimenez N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol 1995;16:32-41.




Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865 78.


Blennerhassett GT, Furth ME, Anderson A, Burn JP, Changanti RS, Blick M, et al. Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia. Leukemia 1988;2:648­57.


Bosl GJ, Bajorin DF, Sheinfeld J, Motzer RJ, Chaganti RS. Cancer of the testis. In: DeVita VT, Hellman S, Rosenberg SA, et al., eds. Cancer, principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams & Wilkins, 2001:1491-518.


Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999;17:501-8.


Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994;219:174-82.


Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.


Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.


Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72:23-7.


Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992;267:2227-8.


Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996;155:3-9.


Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-81.


Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1996; 104:66-73. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996, by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.


Garber, Ken. Spotting Cancer Sooner: Simple but accurate blood tests may soon make it possible to detect cancer while it can still be cured. Technology Review, July/August 2004, 62-68.


Gallup DG, Talledo E. Management of the adnexal mass in the 1990s. South Med J 1997;90:972-81.


Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem 1999;45:630-7.


Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA, et al., eds. Cancer, principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:2537-60.


Heim S, Mitelmann F. Cancer cytogenetics.Chromosomal and molecular genetic

aberrations of tumor cells. 2nd ed. New York: Wiley, 1994.


Hunerbein M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res 1998;146:48­55.


Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.


Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.


Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6.


Kuban DA, El­Mahdi A, Schellhammer PF. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? Semin Oncol 1998;8:72­80.


Liefers G­J, Cleton­Jansen A­M, van de Velde CJH, Hermans J, van Krieken JHJM, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223­8


Ladenson PW. Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Clin Chem 1996;42:183­7.


Marcus, Amy Dockser. Early Warning: A New Way to Find Cancer. Wall Street Journal, December 7, 2004, D1.Cancer 2015- March 22, 2006 10


Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, et al. Preoperative evaluation of serum CA125 levels in premenopausal and postmenopausal patients with pelvic masses:discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6.


McCullough, Marie. Breakthrough Test Fizzled but Underlying Science Holds Promise. 8/7/05.


Melo JV. The molecular biology of chronic myeloid leukemia. Leukemia1996;10:751­6.


Montie JE, Meyers SE. Defining the ideal tumor marker for prostate cancer. Urol Clin North Am 1997;24:247­52.


Olsson CA, Devries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate­specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996;155:1557­62.


National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55(3 pt 2):S4-14.


Pelkey TJ, Frierson HF, Bruns DE. Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin Chem 1996;42:1369­81.


Pegram MD, Pauletti G, Slamon DJ.HER­2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65­77.


Phillips, Michael, et al. Detection of Lung Cancer With Volatile Markers in the Breath. Chest



Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 1998;82:1419­42.


Ristamaki R, Joensuu H, Lappalainen K, Teerenhovi L, Jalkanen S. Elevated serum CD44 level is associated with unfavorable outcome in non­Hodgkin's lymphoma. Blood 1997;90:4039­45.


Shivers SC,Wang X, LiW, Joseph EM, Glass LF, DeConti R, et al. Molecu­ lar staging of malignant melanoma: correlation with clinical outcome. N Engl J Med 1998;280:1410­5.


Silva DM, Kast WM. Vaccination Against Cervical Cancer: Hopes and Realities. American J Cancer, 2005;4:207-219.


Smith RA, Cokkinides V, Eryre HJ. American Cancer Society Guidelines for the Early Detection of Cancer, 2006. CA Cancer J Clin 2006;56:11-25.


Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227­9.


Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5


Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21:215-45.


Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003;124:544-560.


Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5.



loading...











Document Info


Accesari: 11103
Apreciat:

Comenteaza documentul:

Nu esti inregistrat
Trebuie sa fii utilizator inregistrat pentru a putea comenta


Creaza cont nou

A fost util?

Daca documentul a fost util si crezi ca merita
sa adaugi un link catre el la tine in site

Copiaza codul
in pagina web a site-ului tau.




Coduri - Postale, caen, cor

Politica de confidentialitate

Copyright © Contact (SCRIGROUP Int. 2019 )